Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severely active primary Discoid Lupus Erythematosus (DLE) refractory to standard of care.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Horizon Therapeutics Ireland DAC

Criteria

Key Inclusion Criteria:

• Willing and able to understand and provide written informed consent.

• Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.

• A diagnosis of discoid lupus erythematosus for ≥ 6 months prior to screening supported by a history of:

1. A biopsy and/or

2. a clinical feature score of ≥ 7 on the DLE Classification Criteria (DLECC) scale

• Currently active discoid lupus with all the following

1. Digital photography adjudicated with central reading to confirm a currently active discoid disease lesion.

2. CLASI-A score ≥ 8 related to discoid lesions at Baseline

• Treatment refractory DLE

• Women of childbearing potential must have a negative urine pregnancy test on Day 1.

• Nonsterilized male subjects who are sexually active with a woman partner of childbearing potential must agree to use a condom with spermicide from Day 1 and until 3 months (approximately 5 half-lives) after receipt of the last dose.

Key Exclusion Criteria:

• Participation in another clinical study with an investigational drug within 4 weeks prior to Randomization or within 5 published half-lives, whichever is longer.

• Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product (IP) or interpretation of participant safety or trial results.

• Weight > 160 kg (352 pounds) at Screening.

• History of allergy, hypersensitivity reaction, or anaphylaxis to any component of the IP or to a previous monoclonal antibody (mAb) or human immunoglobin (Ig) therapy.

• Breastfeeding or pregnant women or women who intend to become pregnant anytime from signing the informed consent form (ICF) through 6 months after receiving the last dose of IP.

• Splenectomy

• Spontaneous or induced abortion, still or live birth, or pregnancy ≤ 4 weeks prior to Screening through Randomization.

• History of clinically significant cardiac disease including unstable angina, myocardial infarction, congestive heart failure within 6 months prior to Randomization; arrhythmia requiring active therapy, except for clinically insignificant extra systoles, or minor conduction abnormalities.

• History of cancer within the past 5 years, except as follows:

• In situ carcinoma of the cervix treated with apparent success with curative therapy > 12 months prior to Screening, or

• Cutaneous basal cell or squamous cell carcinoma treated with curative therapy.

• Any underlying condition that in the opinion of the Investigator significantly predisposes the participant to infection.

• Known history of a primary immunodeficiency or an underlying condition, such as known human immunodeficiency virus (HIV) infection, or a positive result for HIV infection per central laboratory.

• Confirmed positive test for hepatitis B virus serology defined as:

• Hepatitis B surface antigen, or

• Hepatitis B core antibody

• Positive test for hepatitis C virus antibody unless documented as having had successful treatment of active hepatitis C infection.

• Active tuberculosis (TB), or a positive interferon-gamma release assay (IGRA) test at Screening, unless documented history of appropriate treatment for active or latent TB. Participants with an indeterminate IGRA test result can repeat the test, but if the repeat test is also indeterminate, they will be excluded.

• Any severe herpes virus family infection (including Epstein-Barr virus, cytomegalovirus (CMV)) at any time prior to Randomization, including, but not limited to, disseminated herpes, herpes encephalitis, recent recurrent herpes zoster (defined as 2 episodes within the last 2 years), or ophthalmic herpes.

• Any herpes zoster, cytomegalovirus (CMV), or Epstein-Barr virus infection that was not completely resolved 12 weeks prior to Randomization.

• Opportunistic infection requiring hospitalization or parenteral antimicrobial treatment within 2 years prior to Randomization.

• Any acute illness or evidence of clinically significant active infection on Day 1.

• Participants who have COVID-19 or other significant infection, or in the judgment of the Investigator, may be at a high risk of COVID-19 or its complications should not be randomized.

• Systemic lupus erythematosus defined by fulfilling 2020 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for systemic lupus erythematosus (SLE).

• Current diagnosis of a systemic connective tissue disease.

• Current inflammatory skin disease other than DLE, that, in the opinion of the Investigator, could interfere with the inflammatory skin assessments and confound the disease activity assessments.

• Exposure to an experimental drug either 30 days, 5 half-lives of the agent, or twice the duration of the biological effect of the agent, whichever is longer, prior to Randomization and through the final trial visit.

• Receipt of a live-attenuated vaccine within 4 weeks prior to Randomization.